ARWR - Arrowhead Pharmaceuticals, Inc.
| Previous Close | 6.61 |
| Open | 6.60 |
| Bid | 6.69 x 900 |
| Ask | 6.70 x 400 |
| Day's Range | 6.55 - 6.76 |
| 52 Week Range | 1.42 - 8.09 |
| Volume | 300,458 |
| Avg. Volume | 1,380,320 |
| Market Cap | 582.345M |
| Beta | 1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.48 |
| Earnings Date | May 1, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.25 |
- Business Wire•2 days ago
Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results
Arrowhead Pharmaceuticals Inc. today announced that it will host a webcast and conference call on May 8, 2018, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2018 second quarter ended March 31, 2018.
- Business Wire•15 days ago
Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™
Arrowhead Pharmaceuticals Inc. today announced the presentation of clinical data on ARC-520, the company’s prior generation investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver Congress™ 2018 , the annual meeting of the European Association for the Study of the Liver .
- Business Wire•29 days ago
Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™
Arrowhead Pharmaceuticals Inc. today announced that it will present clinical and pre-clinical data on the company’s investigational medicines for the treatment of chronic hepatitis B infection and liver disease associated with alpha-1 antitrypsin deficiency , at The International Liver Congress™ 2018, the annual meeting of the European Association for the Study of the Liver , being held in Paris from ...
- Business Wire•last month
Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first subjects in a Phase 1/2 clinical study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic hepatitis B virus infection.
- Business Wire•last month
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead Pharmaceuticals Inc. today announced that as an inducement to entering into employment with the Company, on March 16, 2018, the Board of Directors approved "inducement" grants to six new employees under Rule 5635 of the NASDAQ Marketplace Rules.
- Business Wire•last month
Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
- GlobeNewswire•2 months ago
Detailed Research: Economic Perspectives on Etsy, Tiffany, First BanCorp, Deere, Callaway Golf, and Arrowhead Pharmaceuticals — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Business Wire•2 months ago
Arrowhead to Present at Barclays Global Healthcare Conference 2018
Arrowhead Pharmaceuticals Inc. today announced that the company will make a presentation at the following upcoming event:
- ACCESSWIRE•2 months ago
Today’s Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Zosano Pharma
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / U.S. markets rose for the third consecutive session on Monday on the strength of technology shares. The Dow Jones Industrial Average spiked 1.58 percent ...
- Business Wire•2 months ago
Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Arrowhead Pharmaceuticals Inc. today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority and from the local Ethics Committee to proceed with a first-in-human study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
- Business Wire•2 months ago
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT
Arrowhead Pharmaceuticals Inc. today announced the United States Food and Drug Administration has granted orphan drug designation to ARO-AAT, Arrowhead’s second-generation investigational medicine for the treatment of a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
- Business Wire•2 months ago
Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
Arrowhead Pharmaceuticals Inc. today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority and from the local Ethics Committee to proceed with a first-in-human study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic hepatitis B virus infection.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ARWR earnings conference call or presentation 9-Feb-18 9:30pm GMT
Q1 2018 Arrowhead Pharmaceuticals Inc Earnings Call
- Associated Press•2 months ago
Arrowhead Research reports 1Q loss
The Pasadena, California-based company said it had a loss of 18 cents per share. The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
- Business Wire•2 months ago
Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results
Arrowhead Pharmaceuticals Inc. today announced financial results for its fiscal 2018 first quarter ended December 31, 2017. The company is hosting a conference call at 4:30 p.m.
- ACCESSWIRE•2 months ago
Arrowhead Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 9, 2018 / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR ) will be discussing their earnings results in their Q1 Earnings Call to be held on February 9, 2018 at 4:30 ...
- Barrons.com•3 months ago
[$$] OppenheimerFunds' Big Biotech Stock Buys
Krishna Memani, chief investment officer of OppenheimerFunds, blasted passive investing in a video on the investment firm’s home page. “Conventional thinking has people believing there are only 500 great companies, and they’re all headquartered in the U.S.,” Memani declares, taking aim at the Standard & Poor’s 500 index, the standard-bearer of exchange-traded fund investing. The firm cut back on its Nektar Therapeutics (NKTR) position as the stock ended 2017 with a fivefold price increase.
- Business Wire•3 months ago
Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results
Arrowhead Pharmaceuticals Inc. today announced that it will host a webcast and conference call on Friday, February 9, 2018, at 4:30 p.m. EST to discuss its financial results for the fiscal 2018 first quarter ended December 31, 2017.
Market Realist•3 months agoTaking Stock of Arrowhead Pharmaceuticals’ Financial Performance
Arrowhead Pharmaceuticals: A Promising Drug Pipeline
Market Realist•3 months agoWhat Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?
Arrowhead Pharmaceuticals: A Promising Drug Pipeline
- Market Realist•3 months ago
Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases
Arrowhead Pharmaceuticals: A Promising Drug Pipeline
- Market Realist•3 months ago
Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform
Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle. In November 2016, the company announced that it would be discontinuing all clinical programs that utilized EX1 and refocusing its efforts on therapies that exclusively utilize Arrowhead’s targeted RNAi molecule (or TRIM) platform. Therapies based on the TRiM platform have demonstrated high levels of pharmacologic activity in numerous animal models that span several therapeutic areas.
Market Realist•3 months agoAnalysts’ Recommendations for Arrowhead and Its Peers
Incorporated in Delaware, Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them. The therapies developed by Arrowhead make use of a broad portfolio of RNA chemistries and efficient modes of delivery to trigger an RNA interference mechanism that induces the rapid and durable knockdown of the target genes. RNA interference or (RNAi) is a mechanism that inhibits the expression of a specific gene.
- Business Wire•3 months ago
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million
Arrowhead Pharmaceuticals Inc. today announced that on January 22, 2018 it closed the previously announced underwritten public offering of 11,500,000 shares of its common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares.
- Business Wire•3 months ago
Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
Arrowhead Pharmaceuticals Inc. today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price of $5.25 per share, before underwriting discounts.
